Tags

Type your tag names separated by a space and hit enter

Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration.
Ophthalmic Res 2006; 38(6):324-8OR

Abstract

BACKGROUND

Intravitreal triamcinolone acetonide has been discussed as treatment for exudative age-related macular degeneration (AMD).

OBJECTIVES

To give an updated report on repeated intravitreal injections of triamcinolone acetonide (IVTA) for the treatment of exudative AMD.

METHODS

The case-series study included 24 patients (24 eyes) with progressive exudative AMD who had shown an increase in, or stabilization of, visual acuity after a first IVTA, and who eventually experienced a deterioration of visual acuity. The 24 (6.5%) eyes were selected out of a total group of 369 eyes who had received IVTA for exudative AMD within the last 5 years. All patients of the study received a second IVTA (approximately 20 mg) 3.7-38.5 months after the first injection. Main outcome measure was visual acuity.

RESULTS

After the first injection, best corrected visual acuity improved significantly (p = 0.001) from 0.75 +/- 0.34 logMAR to a minimum of 0.58 +/- 0.30 logMAR during follow-up, with 10 (42%) eyes improving in visual acuity by two or more Snellen lines. Towards the end of follow-up after the first injection, best corrected visual acuity decreased significantly (p = 0.03) compared with the baseline value. After the second injection, visual acuity did not change markedly from baseline to a mean maximal visual acuity during follow-up. Comparing the last postoperative examination at the end of the follow-up after the second IVTA with the preoperative examination, a significantly (p = 0.001) higher number of eyes lost in visual acuity [19 (79%) eyes] than gained in visual acuity [3 (12%) eyes].

CONCLUSIONS

In selected eyes with an increase in visual acuity after a first IVTA (20 mg), repeated IVTA temporarily stabilizes visual acuity with a drop in visual acuity towards the end of follow-up.

Authors+Show Affiliations

Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany. Jonst.Jonas@augen.ma.uni-heidelberg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17047404

Citation

Jonas, Jost B., et al. "Repeated Intravitreal Injection of Triamcinolone for Exudative Age-related Macular Degeneration." Ophthalmic Research, vol. 38, no. 6, 2006, pp. 324-8.
Jonas JB, Spandau UH, Kamppeter BA, et al. Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration. Ophthalmic Res. 2006;38(6):324-8.
Jonas, J. B., Spandau, U. H., Kamppeter, B. A., Vossmerbaeumer, U., & Harder, B. (2006). Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration. Ophthalmic Research, 38(6), pp. 324-8.
Jonas JB, et al. Repeated Intravitreal Injection of Triamcinolone for Exudative Age-related Macular Degeneration. Ophthalmic Res. 2006;38(6):324-8. PubMed PMID: 17047404.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration. AU - Jonas,Jost B, AU - Spandau,Ulrich H, AU - Kamppeter,Bernd A, AU - Vossmerbaeumer,Urs, AU - Harder,Bjoern, Y1 - 2006/10/13/ PY - 2005/12/12/received PY - 2006/06/06/accepted PY - 2006/10/19/pubmed PY - 2006/12/19/medline PY - 2006/10/19/entrez SP - 324 EP - 8 JF - Ophthalmic research JO - Ophthalmic Res. VL - 38 IS - 6 N2 - BACKGROUND: Intravitreal triamcinolone acetonide has been discussed as treatment for exudative age-related macular degeneration (AMD). OBJECTIVES: To give an updated report on repeated intravitreal injections of triamcinolone acetonide (IVTA) for the treatment of exudative AMD. METHODS: The case-series study included 24 patients (24 eyes) with progressive exudative AMD who had shown an increase in, or stabilization of, visual acuity after a first IVTA, and who eventually experienced a deterioration of visual acuity. The 24 (6.5%) eyes were selected out of a total group of 369 eyes who had received IVTA for exudative AMD within the last 5 years. All patients of the study received a second IVTA (approximately 20 mg) 3.7-38.5 months after the first injection. Main outcome measure was visual acuity. RESULTS: After the first injection, best corrected visual acuity improved significantly (p = 0.001) from 0.75 +/- 0.34 logMAR to a minimum of 0.58 +/- 0.30 logMAR during follow-up, with 10 (42%) eyes improving in visual acuity by two or more Snellen lines. Towards the end of follow-up after the first injection, best corrected visual acuity decreased significantly (p = 0.03) compared with the baseline value. After the second injection, visual acuity did not change markedly from baseline to a mean maximal visual acuity during follow-up. Comparing the last postoperative examination at the end of the follow-up after the second IVTA with the preoperative examination, a significantly (p = 0.001) higher number of eyes lost in visual acuity [19 (79%) eyes] than gained in visual acuity [3 (12%) eyes]. CONCLUSIONS: In selected eyes with an increase in visual acuity after a first IVTA (20 mg), repeated IVTA temporarily stabilizes visual acuity with a drop in visual acuity towards the end of follow-up. SN - 0030-3747 UR - https://www.unboundmedicine.com/medline/citation/17047404/Repeated_intravitreal_injection_of_triamcinolone_for_exudative_age_related_macular_degeneration_ L2 - https://www.karger.com?DOI=10.1159/000096226 DB - PRIME DP - Unbound Medicine ER -